CytomX Therapeutics Inc (CTMX)
0.89
+0.02
(+2.71%)
USD |
NASDAQ |
Nov 22, 16:00
0.8913
0.00 (0.00%)
After-Hours: 20:00
CytomX Therapeutics Revenue (Annual): 101.21M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 101.21M |
| December 31, 2022 | 53.16M |
| December 31, 2021 | 37.31M |
| December 31, 2020 | 68.43M |
| December 31, 2019 | 26.90M |
| December 31, 2018 | 59.50M |
| Date | Value |
|---|---|
| December 31, 2017 | 71.62M |
| December 31, 2016 | 15.04M |
| December 31, 2015 | 7.712M |
| December 31, 2014 | 5.077M |
| December 31, 2013 | 0.888M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
26.90M
Minimum
2019
101.21M
Maximum
2023
57.40M
Average
53.16M
Median
2022
Revenue (Annual) Benchmarks
| Spero Therapeutics Inc | 96.74M |
| NovaBay Pharmaceuticals Inc | 14.73M |
| Palatin Technologies Inc | 4.490M |
| iBio Inc | 0.225M |
| Theriva Biologics Inc | -- |